



ASX Limited
Market Announcements Office

By electronic lodgement

Sale of Former CEO's Shares

5 August 2013, Melbourne: Australian drug delivery technology company Phosphagenics Limited (ASX: POH; OTCQX: PPGNY) (the Company) has been notified that the shares held by its former CEO have been sold on the market under an irrevocable direction from Dr Esra Ogru. The proceeds from this sale of approximately \$570,000 will be received by the Company upon settlement as the first restitution of identified misappropriated funds.

The Company has taken steps to secure other assets of persons referred to in its announcement of 24 July 2013 and remains confident of recovering a substantial proportion of the misappropriated funds.

ENDS

Enquiries

All Media:

Rudi Michelson
Monsoon Communications
+61 3 9620 3333

Shareholders:

David Segal
Investor Relations Manager
Phosphagenics Limited
+61 3 9565 1103

About Phosphagenics

Phosphagenics Limited is commercialising drug delivery applications based on its novel transdermal (drugs administered via skin) TPM[®] – Targeted Penetration Matrix technology. TPM[®] is a patient friendly and cost effective system used to deliver proven pharmaceutical and nutraceutical products.

The lead products advancing through clinical trials are an oxycodone and oxymorphone matrix system for the relief of chronic pain.

Phosphagenics' shares are listed on the Australian Securities Exchange (POH) and its ADR – Level 1 program in the US is with The Bank of New York Mellon (PPGNY).

www.phosphagenics.com